Gabapentin-induced severe myoclonus in a patient with impaired renal function.
Journal of Neurology (Impact Factor: 3.84). 04/2006; 253(3):382-3. DOI: 10.1007/s00415-005-0970-1
ABSTRACT Without Abstract
- Journal of the Formosan Medical Association 09/2014; 113(9):660–661. · 1.70 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Gabapentin, an AED approved for the adjunctive treatment of partial seizures with/without secondary generalization and for the treatment of postherpetic neuralgia, is frequently used off-label for the treatment of both psychiatric and pain disorders. Since gabapentin is cleared solely by renal excretion, dosing requires consideration of the patient's renal function. Myoclonic activity may occur as a complication of gabapentin toxicity, especially with acute kidney injury or end-stage renal disease. We report 2 cases of myoclonic activity associated with gabapentin toxicity in the setting of renal disease which resolved with discontinuation of gabapentin and treatment with hemodialysis and peritoneal dialysis. As gabapentin has multiple indications and off-label uses, an understanding of myoclonus, neurotoxicity, and renal dosing is important to clinicians in multiple specialties.Epilepsy & Behavior Case Reports. 01/2014; 2:8–10.
Conference Paper: Multiresolution stereo by simulated annealing[Show abstract] [Hide abstract]
ABSTRACT: Maximum a posteriori (MAP) estimation of depth based on the Bayesian approach is described. The authors investigate simulated annealing in a hierarchical pyramid to accelerate the convergence. They also utilize an unobservable line process to recover the piecewise continuous depth map over the image plane. Simulation results are provided using random dot diagrams as well as synthesized imagesNeural Networks, 1990., 1990 IJCNN International Joint Conference on; 07/1990
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.